Comprehensive Evaluation of COVID-19 Patient Short- and Long-term Outcomes:

Disparities in Healthcare Utilization and Post-Hospitalization Outcomes

Stephen Salerno,¹ Yuming Sun,¹ Emily Morris,¹ Xinwei He,¹ Yajing Li,¹ Ziyang Pan,¹ Peisong Han,¹ Jian Kang,¹ Michael W. Sjoding,² and Yi Li,¹,*

¹Department of Biostatistics, University of Michigan, Ann Arbor, MI
²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

*Correspondence: Yi Li, PhD; E: yili@umich.edu; T: 734-647-5766, M2102, 1415 Washington Heights, Ann Arbor, MI 48109-2029 June 25, 2021

Word Count: 3,352

Number of Text Pages: 19

Number of References: 106

Number of Figures/Tables: 6
Abstract

Background
Understanding risk factors for short- and long-term COVID-19 outcomes have implications for current guidelines and practice. We study whether early identified risk factors for COVID-19 persist one year later and through varying disease progression trajectories.

Methods
This was a retrospective study of 6,731 COVID-19 patients presenting to Michigan Medicine between March 10, 2020 and March 10, 2021. We describe disease progression trajectories from diagnosis to potential hospital admission, discharge, readmission, or death. Outcomes pertain to all patients: rate of medical encounters, hospitalization-free survival, and overall survival, and hospitalized patients: discharge versus in-hospital death and readmission. Risk factors included patient age, sex, race, body mass index, and 29 comorbidity conditions.

Results
Younger, non-Black patients utilized healthcare resources at higher rates, while older, male, and Black patients had higher rates of hospitalization and mortality. Diabetes with complications, coagulopathy, fluid and electrolyte disorders, and blood loss anemia were risk factors for these outcomes. Diabetes with complications, coagulopathy, fluid and electrolyte disorders, and blood loss were associated with lower discharge and higher inpatient mortality rates.

Conclusions
This study found differences in healthcare utilization and adverse COVID-19 outcomes, as well as differing risk factors for short- and long-term outcomes throughout disease progression. These findings may inform providers in emergency departments or critical care settings of treatment.
priorities, empower healthcare stakeholders with effective disease management strategies, and
aid health policy makers in optimizing allocations of medical resources.
Introduction

On March 10, 2020, the first confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported in the state of Michigan.[1] Since then, Southeast Michigan quickly evolved into an endemic center in the first wave of the pandemic, characterized by several densely populated urban areas, including Detroit.[2] Over the course of one year, the extent of the ensuing pandemic has changed drastically. More than 600,000 individuals in this country have died as a result of COVID-19,[3] with more than 21,000 from Michigan.[4, 5] The country was devastated with a healthcare crisis and economic wreckage,[6, 7] with medical resources depleted in endemic centers[8, 9] and roughly 20 million jobs lost nationwide.[10] More than 25% of American families currently experience financial hardship.[11, 12]

A growing body of literature has identified risk factors for COVID-19 outcomes, including older age,[13] male sex,[14] higher body mass index,[13] and comorbidity conditions such as cardiovascular disease,[15] diabetes,[16] chronic respiratory disease,[16, 17] hypertension,[18] and cancer.[19] Evidence of racial, ethnic,[20–23] and socioeconomic disparity[20, 22] in COVID-19 outcomes has further punctuated the clinical and broader societal impact of the pandemic.[24, 25] However, much of this early work that reported on the first wave of the pandemic was potentially limited by sample size or follow-up duration.[26–28] Further, most of this work relied on risk factors collected during the early phase of the pandemic.[29–31] As the effects of the pandemic have extended over the past year and into the foreseeable future, and the demographics of new cases are constantly changing,[32] it is pertinent to re-examine these risk factors for adverse outcomes in the context of new information.[33] Because of the limited scope of data, most previous work focused on one or two outcomes of COVID-19 patients,[13–16] lacking a comprehensive evaluation of disease
progression. Indeed, owing to a longer follow-up available, especially among the earliest of cases in Southeast Michigan, it warranted studying outcomes that were less understood, such as healthcare utilization over time and competing hospitalization outcomes.

There is substantial interest to study COVID-19 outcomes in localized regions, such as Southeast Michigan, as it may lead to better allocation of healthcare resources and more effective preventive and disease management measures for those regions hit hardest by the pandemic.[20, 34, 35] One year after the first reported case in Michigan, this study sought to re-evaluate these proximate outcomes among COVID-19 patients in this early hotspot and examine the relationship between previously-identified risk factors and a variety of short- and long-term outcomes.

The University of Michigan (UM) Health System, referred to as Michigan Medicine hereafter, is one of the primary regional centers managing the care of COVID-19 patients [36, 37] and has created, maintained, and updated an electronic medical record (EMR) database for COVID-19 patients treated in its hospital system since the outbreak.[38] Access to this rich database enables us to conduct a comprehensive analysis of COVID-19 outcomes. In the following, we describe the disease progression trajectories of COVID-19 patients, from a positive test to potential hospital admissions, discharge, readmission post-discharge, or death. We then show modeling results for these outcomes on risk factors established in previous work.[13–19] We determine which of these risk factors persist as predictors for severe outcomes beyond the initial outbreak and throughout the past year as infections became more widespread. Our results have implications for current public health guidelines and policy, as COVID-19 has fundamentally changed the landscape of healthcare utilization.
Materials and Methods

Study Population

This was a retrospective study, approved by the UM Institutional Review Board, on multiple outcomes of COVID-19 patients and their associated risk factors. Included were COVID-19 patients who were treated at Michigan Medicine between March 10, 2020 and March 10, 2021. These patients were tested positive either at Michigan Medicine or elsewhere, with a positive test referring to a result of “detected,” “presumptive positive,” or “positive” obtained via reverse transcription polymerase chain reaction (PCR) tests on samples collected from sputum or from nasopharyngeal or oropharyngeal swabs (diagnosis code of U07.1 or U07.2). A small proportion of patients who transferred in and were tested elsewhere did not have dates or test results confirmed in their laboratory records, and, thus, had to be removed from our analysis. Our analyzable population was 6,731 patients with a positive COVID-19 diagnosis and available demographic and clinical data between March 10, 2020 and March 10, 2021 in the Michigan Medicine EMR. Their outcomes, demographic information, and clinical characteristics are described herein.

Outcomes

Outcomes were categorized into three groups: those pertaining to all COVID-19 patients (1a-1c), those pertaining to hospitalized patients (2a-2c), and those for sensitivity analyses (3a-3b). They include:

- 1a. Rate of Medical Encounters: defined by each patient’s number of encounters with Michigan Medicine from COVID-19 diagnosis until the end of the study (March 10, 2021) divided by the number of days they were at risk.
• 1b. Hospitalization-Free Survival:[39, 40] measured as the time from COVID-19 diagnosis to first admission date or death, whichever came first, subject to censoring by the end of this study.

• 1c. Overall Survival: the time from diagnosis until death or administrative censoring at the end of the study.

• 2a-b. Discharge versus In-Hospital Death: the time from the admission date to (2a) discharge or (2b) in-hospital death, two competing short-term outcomes of hospitalization.

• 2c. Readmission: a binary variable indicating whether a patient was re-admitted at any point after discharge from their first hospitalization.

• 3a. Post-Admission Mortality: the time from patient’s first admission date post-diagnosis until death, possibly censored by the end of the study. This was to check the consistency of the results in 2a-b by incorporating any death, rather than only in-hospital death.

• 3b. COVID-Induced Hospitalizations/Readmissions: we restricted hospitalizations to COVID-specific admissions, and similarly, COVID-related readmissions following a COVID-19 hospitalization. This was to check the robustness of the results in 2a-c by only focusing on COVID-induced hospitalizations and readmissions.

Demographic and Clinical Characteristics

We identified demographic data for all patients, including age, sex, race, and body mass index. Due to the homogeneity of the patient population at Michigan Medicine, patient’s self-identified race was classified into three groups: Black, non-Black, or Unknown. Similarly, due to few patients identifying as Hispanic or Latinx (< 5%), we excluded patient ethnicity as a potential covariate. Using available International Classification of Diseases, Tenth Revision (ICD-10)
codes [41] (Supplement A, Table S1) from patient encounters, we constructed indicators for 29 of the 30 comorbidity conditions used in the Elixhauser comorbidity index,[42–44] the only exception being HIV/AIDS status due to its unavailability. Collectively, these comorbidity conditions were reported to be predictive of in-hospital and post-discharge mortality in numerous non-COVID [45–47] and COVID-19 settings.[15, 48–54]

**Statistical Analysis**

We studied a natural disease progression by sequentially modeling the COVID-19 outcomes defined in above; see Figure 1 for a flow diagram depicting relationships between at-risk populations, patient outcomes, and corresponding models. First, to assess healthcare utilization among all COVID-positive patients, we modelled the associations of all potential risk factors with the rate of medical encounters in Poisson regression.[55] Patient who died before the end of the study were excluded from this model to mitigate survivorship bias. This was used as a proxy measure for healthcare utilization post-diagnosis, an outcome seldom investigated by the COVID-19 literature. We then studied the impact of risk factors on hospitalization-free survival and overall survival using Cox proportional hazards regression models.[56] Among hospitalized patients, we accounted for the competing relationship between two short-term outcomes of hospitalization, that is, discharge versus in hospital death, using the Fine-Gray subdistribution regression model;[57] see Supplement B for a more detailed description of the model. Finally, we modeled the odds of readmission among discharged patients using a logistic regression model.

[FIGURE 1 ABOUT HERE]

**Figure 1**: Diagram of disease progression for $N = 6,731$ COVID-19 patients, and the relationship between the patient outcomes, patient sub-populations, and models in our analytic workflow.
Results

Patient Outcomes and Characteristics

Among 6,731 analyzable patients with a positive COVID-19 diagnosis, 947 (14%) were hospitalized at or after diagnosis and 153 died (2%) during the follow-up period. Among those hospitalized, 840 (89%) were discharged and 160 (17%) were subsequently readmitted. We observed 134 deaths among hospitalized patients: 107 (81%) in-hospital deaths, i.e., deaths before discharge from their first (index) hospitalization, 17 (12%) after their index discharge, and 10 (7%) after readmission; see Figure 1.

On average, these 6,731 COVID-19 patients were 44 years old and majority female (56%), with an over-representation of Black patients (15%) as compared to the general population surrounding Michigan Medicine. There was a high proportion of patients with cardiac arrhythmias (27%), hypertension (32% uncomplicated, 9% complicated), chronic pulmonary disease (26%), obesity (28%), and fluid and electrolyte disorders (20%; Table 1). Of note, a total of 539 (8%) patients did not disclose their race; Table S2 (Supplement A) shows they were, in general, much younger and healthier than those who identified their race.
Table 1: Descriptive characteristics for COVID-19 patients treated at Michigan Medicine between March 10, 2020 and March 10, 2021. Summary statistics are for the overall population, those admitted for an inpatient stay during the follow-up period, and those readmitted post-discharge.

| Characteristic                                      | All Patients | Hospitalized Patients | Readmitted Patients |
|-----------------------------------------------------|--------------|-----------------------|---------------------|
|                                                     | N = 6,731\(^a\) | N = 947\(^a\) | N = 160\(^a\) |
| Age (years)                                         | 44 (24, 60) | 60 (46, 71) | 61 (40, 73) |
| Sex                                                 |              |                      |                     |
| Female                                              | 3,706 (56%) | 430 (45%) | 59 (37%) |
| Male                                                | 2,952 (44%) | 517 (55%) | 101 (63%) |
| Race                                                |              |                      |                     |
| White                                               | 4,560 (68%) | 518 (55%) | 99 (62%) |
| Black                                               | 1,025 (15%) | 305 (32%) | 49 (31%) |
| Asian                                               | 252 (3.7%) | 29 (3.1%) | 5 (3.1%) |
| Multicultural/Other                                 | 315 (4.7%) | 43 (4.5%) | 6 (3.8%) |
| Unknown                                             | 579 (8.6%) | 52 (5.5%) | 1 (0.6%) |
| Ethnicity                                           |              |                      |                     |
| Non-Hispanic or Latino                              | 5,741 (85%) | 867 (92%) | 156 (98%) |
| Hispanic or Latino                                  | 267 (4.0%) | 25 (2.6%) | 3 (1.9%) |
| Unknown                                             | 579 (8.6%) | 52 (5.5%) | 1 (0.6%) |
| Body Mass Index (kg/m2)                             | 30 (28, 30) | 30 (26, 36) | 27 (24, 34) |
| Congestive Heart Failure                            | 582 (8.6%) | 235 (25%) | 54 (34%) |
| Cardiac Arrhythmias                                 | 1,797 (27%) | 587 (62%) | 133 (83%) |
| Valvular Disease                                    | 391 (5.8%) | 111 (12%) | 34 (21%) |
| Pulmonary Circulation Disorders                     | 399 (5.9%) | 187 (20%) | 48 (30%) |
| Peripheral Vascular Disorders                       | 543 (8.1%) | 193 (20%) | 61 (38%) |
| Hypertension, Uncomplicated                         | 2,139 (32%) | 636 (67%) | 123 (77%) |
| Hypertension, Complicated                           | 627 (9.3%) | 336 (35%) | 74 (46%) |
| Paralysis                                           | 138 (2.1%) | 61 (6.4%) | 23 (14%) |
| Other Neurological Disorders                        | 616 (9.2%) | 246 (26%) | 66 (41%) |
| Chronic Pulmonary Disease                           | 1,730 (26%) | 370 (39%) | 72 (45%) |
| Diabetes, Uncomplicated                             | 1,049 (16%) | 383 (40%) | 71 (44%) |
| Diabetes, Complicated                               | 743 (11%) | 330 (35%) | 64 (40%) |
| Hypothyroidism                                      | 715 (11%) | 151 (16%) | 34 (21%) |
| Renal Failure                                       | 744 (11%) | 334 (35%) | 72 (45%) |
| Liver Disease                                       | 710 (11%) | 186 (20%) | 52 (32%) |
| Lymphoma                                            | 119 (1.8%) | 32 (3.4%) | 5 (3.1%) |
| Metastatic Cancer                                   | 595 (8.8%) | 139 (15%) | 48 (30%) |
| Solid Tumor without Metastasis                      | 674 (10%) | 161 (17%) | 47 (29%) |
| Rheumatoid Arthritis/Collagen Vascular Diseases     | 536 (8.0%) | 98 (10%) | 27 (17%) |
| Coagulopathy                                        | 662 (9.8%) | 298 (31%) | 80 (50%) |
| Obesity                                             | 1,880 (28%) | 443 (47%) | 71 (44%) |
| Weight Loss                                         | 632 (9.4%) | 232 (24%) | 74 (46%) |
| Fluid and Electrolyte Disorders                     | 1,349 (20%) | 632 (67%) | 137 (86%) |
| Blood Loss Anemia                                   | 276 (4.1%) | 121 (13%) | 45 (28%) |
| Deficiency Anemia                                   | 660 (9.8%) | 183 (19%) | 55 (34%) |
| Alcohol Abuse                                       | 285 (4.2%) | 55 (5.8%) | 14 (8.8%) |
| Drug Abuse                                          | 336 (5.0%) | 101 (11%) | 34 (21%) |
| Psychoses                                           | 201 (3.0%) | 84 (8.9%) | 23 (14%) |
| Depression                                          | 1,835 (27%) | 369 (39%) | 99 (62%) |

\(^a\)Median (IQR); n (%)

It is made available under a CC-BY-NC-ND 4.0 International license.
Restricting to the 947 hospitalized patients, we observed a much higher average age of 60 years old and a higher proportion of male (55%) and Black patients (32%), as well as a consistently higher comorbidity burden. Further restricting to the 160 patients with multiple admissions, this trend persisted, with an average age of 61 years old, 83% of patients diagnosed with cardiac arrhythmias, 77% with hypertension, 86% with fluid and electrolyte disorders, and 62% with depressive symptoms.

**Risk Factors for Outcomes among All COVID-19 Patients**

In examining medical utilization among all COVID-19 patients, we found that younger (per 10 years; Incidence Rate Ratio (IRR): 0.97; 95% Confidence Interval (CI): 0.97-0.98) and non-Black (1.02; 1.00-1.03) patients had higher hospital utilization rates, and that 22 of 29 comorbidity conditions were associated with significantly higher hospital utilization rates (Table 2). Cardiac arrhythmias (1.38; 1.36-1.39), fluid and electrolyte disorders (1.50; 1.49-1.52), and blood loss anemia (1.37; 1.35-1.39) were among the most significant comorbidity conditions for increased medical utilization.
Table 2: Adjusted associations of patient demographic and clinical risk factors with COVID-19 outcomes among all COVID-19 patients, based on (a) Poisson regression for the number of encounters each patient had with Michigan Medicine; (b) Cox proportional hazards regression for hospitalization-free survival; (c) Cox proportional hazards regression for overall survival.

| Characteristic                              | Number of Encounters | Overall-Mortality |
|----------------------------------------------|-----------------------|-------------------|
|                                              | IRR (95% CI)a         | HR (95% CI)b      |
| Age (per 10 years)                          | 0.97 (0.97, 0.98)     | 1.69 (1.47, 1.93) |
| Sex                                          |                       |                   |
| Female                                       | —                     | —                 |
| Male                                         | 1.00 (0.99, 1.01)     | 1.34 (0.93, 1.92) |
| Race                                         |                       |                   |
| Black                                        | —                     | —                 |
| Non-Black                                    | 1.02 (1.00, 1.03)     | 0.66 (0.45, 0.98) |
| Unknown                                      | 0.73 (0.71, 0.76)     | 2.57 (1.44, 4.59) |
| Body Mass Index (kg/m²)                      | 0.99 (0.99, 0.99)     | 0.98 (0.96, 1.01) |
| Congestive Heart Failure                     | 1.02 (1.00, 1.03)     | 1.13 (0.75, 1.69) |
| Cardiac Arrhythmias                         | 1.38 (1.36, 1.39)     | 1.61 (1.04, 2.50) |
| Valvular Disease                             | 0.93 (0.92, 0.95)     | 0.91 (0.58, 1.43) |
| Pulmonary Circulation Disorders              | 1.21 (1.20, 1.23)     | 1.09 (0.73, 1.64) |
| Peripheral Vascular Disorders                | 1.10 (1.08, 1.11)     | 0.80 (0.52, 1.21) |
| Hypertension, Uncomplicated                  | 1.21 (1.19, 1.22)     | 0.72 (0.45, 1.16) |
| Hypertension, Complicated                    | 1.06 (1.04, 1.08)     | 1.51 (0.95, 2.41) |
| Paralysis                                    | 1.45 (1.42, 1.48)     | 1.37 (0.71, 2.68) |
| Other Neurological Disorders                 | 1.05 (1.04, 1.07)     | 1.49 (1.03, 2.14) |
| Chronic Pulmonary Disease                    | 1.05 (1.04, 1.06)     | 1.70 (1.19, 2.44) |
| Diabetes, Uncomplicated                      | 0.99 (0.97, 1.00)     | 0.88 (0.54, 1.44) |
| Diabetes, Complicated                        | 1.14 (1.12, 1.16)     | 2.05 (1.24, 3.39) |
| Hypothyroidism                               | 1.12 (1.11, 1.14)     | 0.65 (0.40, 1.05) |
| Renal Failure                                | 0.97 (0.95, 0.98)     | 1.04 (0.68, 1.57) |
| Liver Disease                                | 1.08 (1.07, 1.10)     | 0.93 (0.62, 1.40) |
| Lymphoma                                     | 1.19 (1.16, 1.22)     | 1.39 (0.68, 2.86) |
| Metastatic Cancer                            | 1.22 (1.20, 1.24)     | 1.02 (0.60, 1.73) |
| Solid Tumor without Metastasis               | 1.14 (1.13, 1.16)     | 0.88 (0.54, 1.43) |
| Rheumatoid Arthritis/Collegen Vascular Diseases | 1.21 (1.19, 1.22)  | 0.91 (0.53, 1.55) |
| Coagulopathy                                 | 1.26 (1.24, 1.28)     | 2.02 (1.39, 2.92) |
| Obesity                                      | 1.34 (1.32, 1.36)     | 1.28 (0.85, 1.95) |
| Weight Loss                                  | 1.26 (1.24, 1.27)     | 0.85 (0.57, 1.27) |
| Fluid and Electrolyte Disorders              | 1.50 (1.49, 1.52)     | 5.50 (3.27, 9.23) |
| Blood Loss Anemia                            | 1.37 (1.35, 1.39)     | 2.85 (1.84, 4.40) |
| Deficiency Anemia                            | 1.06 (1.05, 1.08)     | 0.44 (0.28, 0.69) |
| Alcohol Abuse                                | 0.94 (0.92, 0.96)     | 0.71 (0.37, 1.37) |
| Drug Abuse                                    | 0.97 (0.95, 0.98)     | 0.95 (0.52, 1.74) |
| Psychoses                                    | 0.99 (0.97, 1.01)     | 1.06 (0.63, 1.80) |
| Depression                                   | 1.33 (1.32, 1.35)     | 0.60 (0.41, 0.89) |

aIRR = Incidence Rate Ratio, CI = Confidence Interval, HR = Hazard Ratio
bBold values indicate statistical significance
We further identified several risk factors that persisted as significant predictors of acute outcomes, namely hospitalization-free survival and overall survival. Older (per 10 years; Hazard Ratio (HR): 1.23; 95% CI: 1.18-1.28), male (1.34; 1.16-1.54), and Black patients (1.89; 95% CI: 1.61-2.17) had higher hospitalization hazards. Additionally, ten comorbidity conditions were associated with higher hazards of hospitalization: cardiac arrhythmias (1.77; 1.51-2.07), pulmonary circulation disorders (1.27; 1.05-1.53), hypertension with (1.21; 1.01-1.45) and without complications (1.49; 1.22-1.83), other neurological disorders (1.35; 1.14-1.60), diabetes with complications (1.28; 1.02-1.60), coagulopathy (1.87; 1.60-2.20), weight loss (1.22; 1.03-1.44), fluid and electrolyte disorders (4.48; 3.78-5.30), and blood loss anemia (1.32; 1.06-1.64), while five were associated with lower hospitalization hazards: valvular disease (0.71; 0.57-0.89), liver disease (0.79; 0.67-0.95), rheumatoid arthritis/collagen vascular diseases (0.80; 0.64-0.99), deficiency anemia (0.70; 0.58-0.84), and alcohol abuse (0.62; 0.46-0.83; see Supplement C, Table S3). Considering overall survival, older (per 10 years; HR: 1.69; 95% CI: 1.47-1.93) and Black patients (1.52; 1.02-2.22), as well as those with cardiac arrhythmias (1.61; 1.04-2.50), chronic pulmonary disease (1.70; 1.19-2.44), diabetes with complications (2.05; 1.24-3.39), coagulopathy (2.02; 1.39-2.92), fluid and electrolyte disorders (5.50; 3.27-9.23), and blood loss anemia (2.85; 1.84-4.40), had significantly higher mortality (Table 2).

**Risk Factors for Post-Hospitalization Outcomes**

Among patients hospitalized after COVID-19 diagnosis, we modeled in-hospital death versus discharge, two competing hospitalization outcomes, using the Fine-Gray subdistribution hazards model (Table 3). Older age (per 10 years) was associated with a 9% lower discharge rate (Subdistribution Hazard Ratio (SHR): 0.91; 95% CI: 0.86-0.95) and a 50% higher in-hospital mortality rate (SHR: 1.50; 95% CI: 1.27-1.77) post-diagnosis. Diabetes with complications...
(Discharge: 0.71; 0.57-0.88; Mortality: 1.82; 1.00-3.33), coagulopathy (Discharge: 0.71; 0.61-0.84; Mortality: 1.72; 1.15-2.56), fluid and electrolyte disorders (Discharge: 0.70; 0.60-0.82; Mortality: 2.57; 1.30-5.07), and blood loss anemia (Discharge: 0.67; 0.53-0.85; Mortality: 2.68; 1.66-4.32) were associated with lower discharge and higher inpatient mortality rates. Additionally, male sex (0.82; 0.71-0.95), cardiac arrhythmias (0.85; 0.73-0.99), and other neurological disorders (0.73; 0.61-0.87) were associated with lower discharge rates, while chronic pulmonary disease (1.69; 1.12-2.55) was associated with higher inpatient mortality. In contrast, solid tumor cancers (1.27; 1.01-1.59), rheumatoid arthritis/collagen vascular diseases (1.34; 1.07-1.68), and drug abuse (1.31; 1.03-1.67) were associated with higher discharge rates, while weight loss (0.53; 0.31-0.90), deficiency anemia (0.44; 0.24-0.82), and depression (0.57; 0.34-0.97) were associated with lower inpatient mortality rates (Table 3). In a sensitivity analysis, we restricted our competing risks analysis to patients hospitalized directly due to COVID-19 and found similar patterns of associations (Supplement D, Table S5).
Table 3: Adjusted associations of patient demographic and clinical risk factors with COVID-19 outcomes among hospitalized COVID-19 patients, based on Fine-Gray subdistribution hazards regression for (a) discharge post-admission and (b) in-hospital death post-admission and logistic regression for (c) whether the patient was readmitted at any point post-index discharge.

| Characteristic                                           | Discharge SHR (95% CI)\(^a\) | In-Hospital Death SHR (95% CI)\(^b\) |
|----------------------------------------------------------|-------------------------------|--------------------------------------|
| Age (per 10 years)                                       |                               |                                      |
| Female                                                   | ---                           | ---                                  |
| Male                                                     | 0.82 (0.71, 0.95)              | 1.38 (0.85, 2.23)                    |
| Sex                                                      |                               |                                      |
| Race                                                     |                               |                                      |
| Black                                                    |                                 |                                      |
| Non-Black                                                | 1.12 (0.96, 1.30)              | 0.69 (0.43, 1.12)                    |
| Unknown                                                  | 0.47 (0.31, 0.69)              | 2.42 (1.22, 4.77)                    |
| Body Mass Index (kg/m\(^2\))                            | 1.00 (0.99, 1.01)              | 0.97 (0.94, 1.01)                    |
| Congestive Heart Failure                                 | 0.88 (0.72, 1.09)              | 1.31 (0.80, 2.16)                    |
| Cardiac Arrhythmias                                      | 0.85 (0.73, 0.99)              | 1.42 (0.83, 2.44)                    |
| Valvular Disease                                         | 1.17 (0.91, 1.51)              | 0.99 (0.55, 1.79)                    |
| Pulmonary Circulation Disorders                          | 0.84 (0.70, 1.01)              | 1.02 (0.64, 1.62)                    |
| Peripheral Vascular Disorders                            | 1.20 (0.98, 1.46)              | 0.75 (0.44, 1.26)                    |
| Hypertension, Uncomplicated                              | 1.01 (0.85, 1.19)              | 0.72 (0.43, 1.20)                    |
| Hypertension, Complicated                                | 1.18 (0.96, 1.46)              | 0.86 (0.48, 1.52)                    |
| Paralysis                                                | 1.12 (0.86, 1.45)              | 0.79 (0.30, 2.08)                    |
| Other Neurological Disorders                             | 0.73 (0.61, 0.87)              | 1.44 (0.94, 2.19)                    |
| Chronic Pulmonary Disease                               | 0.87 (0.75, 1.01)              | 1.70 (1.13, 2.55)                    |
| Diabetes, Uncomplicated                                  | 1.09 (0.89, 1.33)              | 0.91 (0.51, 1.62)                    |
| Diabetes, Complicated                                    | 0.71 (0.57, 0.88)              | 1.82 (1.00, 3.33)                    |
| Hypothyroidism                                           | 1.05 (0.86, 1.28)              | 0.65 (0.32, 1.30)                    |
| Renal Failure                                            | 0.89 (0.73, 1.08)              | 1.12 (0.68, 1.86)                    |
| Liver Disease                                            | 0.98 (0.81, 1.18)              | 1.21 (0.75, 1.96)                    |
| Lymphoma                                                 | 0.69 (0.43, 1.11)              | 1.63 (0.66, 4.03)                    |
| Metastatic Cancer                                        | 1.18 (0.91, 1.53)              | 0.99 (0.49, 1.97)                    |
| Solid Tumor without Metastasis                           | 1.27 (1.01, 1.59)              | 0.66 (0.34, 1.26)                    |
| Rheumatoid Arthritis/Collagen Vascular Diseases          | 1.34 (1.07, 1.68)              | 0.80 (0.36, 1.77)                    |
| Coagulopathy                                             | 0.71 (0.61, 0.84)              | 1.61 (1.07, 2.42)                    |
| Obesity                                                  | 0.99 (0.83, 1.17)              | 1.53 (0.94, 2.49)                    |
| Weight Loss                                              | 0.90 (0.77, 1.05)              | 0.53 (0.31, 0.90)                    |
| Fluid and Electrolyte Disorders                          | 0.70 (0.60, 0.82)              | 2.57 (1.30, 5.07)                    |
| Blood Loss Anemia                                        | 0.67 (0.53, 0.85)              | 2.68 (1.66, 4.32)                    |
| Deficiency Anemia                                        | 1.09 (0.90, 1.33)              | 0.44 (0.24, 0.82)                    |
| Alcohol Abuse                                            | 1.18 (0.86, 1.61)              | 0.61 (0.27, 1.40)                    |
| Drug Abuse                                               | 1.31 (1.03, 1.67)              | 0.81 (0.34, 1.92)                    |
| Psychoses                                                | 0.94 (0.71, 1.23)              | 1.12 (0.58, 2.15)                    |
| Depression                                               | 1.06 (0.92, 1.23)              | 0.57 (0.34, 0.97)                    |

\(^a\)SHR = Subdistribution Hazard Ratio, CI = Confidence Interval
\(^b\)Bold values indicate statistical significance
In a second sensitivity analysis, we considered risk factors leading to post-admission mortality among hospitalized patients. Post-admission survival was defined as the time lag between the patient’s first admission date post-diagnosis and death, subject to administrative censoring on March 10, 2021. Figure 2 plots Kaplan-Meier curves for post-admission survival, stratified by age quartiles, chronic pulmonary disease, coagulopathy, fluid and electrolyte disorders, blood loss anemia, and depression, which were significantly associated with post-admission mortality using univariate log-rank tests.

Figure 2: Kaplan-Meier curves for post-admission mortality among hospitalized COVID-19 patients, stratified by (A) age quartiles, (B) chronic pulmonary disease, (C) coagulopathy, (D) fluid and electrolyte disorders, (E) blood loss anemia, and (F) depression.

We then used a Cox regression model to detect risk factors associated with post-admission mortality among hospitalized patients, adjusting for all other factors. Differing from our competing risks analysis, this model defines the event of interest to be death at any point following an inpatient stay, including among patients who died post-discharge. We found that older age (per 10 years) was associated with 45% higher post-admission mortality hazard (HR: 1.45; 95% CI: 1.25-1.68) and that chronic pulmonary disease (1.63; 1.12-2.37), coagulopathy (1.54; 1.05-2.26), fluid and electrolyte disorders (2.90; 1.57-3.69), and blood loss anemia (2.33; 1.47-3.69) were significantly associated with higher mortality rates, while hypertension without complications (0.61; 0.38-1.00) and depression (0.65; 0.42-1.00) were associated with lower mortality rates (Table 4).
### Table 4: Adjusted associations of patient demographic and clinical risk factors with COVID-19 outcomes among hospitalized COVID-19 patients, based on a Cox proportional hazards regression for time to any death post-admission.

| Characteristic                                               | Post-Admission Mortality |
|--------------------------------------------------------------|--------------------------|
|                                                             | HR (95% CI)¹              |
| Age (per 10 years)                                          | 1.45 (1.25, 1.68)        |
| Sex                                                         |                          |
| Female                                                      | —                        |
| Male                                                        | 1.28 (0.86, 1.90)        |
| Race                                                        |                          |
| Black                                                       | —                        |
| Non-Black                                                   | 0.90 (0.59, 1.38)        |
| Unknown                                                     | 3.04 (1.67, 5.56)        |
| Body Mass Index (kg/m²)                                     | 0.98 (0.95, 1.01)        |
| Congestive Heart Failure                                    | 1.21 (0.77, 1.89)        |
| Cardiac Arrhythmias                                         | 1.51 (0.93, 2.45)        |
| Valvular Disease                                            | 0.91 (0.55, 1.51)        |
| Pulmonary Circulation Disorders                             | 1.04 (0.68, 1.58)        |
| Peripheral Vascular Disorders                               | 0.95 (0.60, 1.50)        |
| Hypertension, Uncomplicated                                 |                          |
| Hypertension, Complicated                                   | 0.61 (0.38, 1.00)        |
| Paralysis                                                   | 1.37 (0.81, 2.32)        |
| Other Neurological Disorders                                | 0.93 (0.44, 1.94)        |
| Chronic Pulmonary Disease                                  | 1.63 (1.12, 2.37)        |
| Diabetes, Uncomplicated                                     | 0.94 (0.56, 1.57)        |
| Diabetes, Complicated                                       | 1.60 (0.96, 2.67)        |
| Hypothyroidism                                              | 0.76 (0.45, 1.28)        |
| Renal Failure                                               | 0.95 (0.60, 1.50)        |
| Liver Disease                                               | 0.93 (0.59, 1.47)        |
| Lymphoma                                                    | 1.42 (0.59, 3.42)        |
| Metastatic Cancer                                           | 1.30 (0.70, 2.42)        |
| Solid Tumor without Metastasis                              | 0.76 (0.42, 1.37)        |
| Rheumatoid Arthritis/Collagen Vascular Diseases             | 0.56 (0.26, 1.18)        |
| Coagulopathy                                                | 1.54 (1.05, 2.26)        |
| Obesity                                                     | 1.33 (0.85, 2.09)        |
| Weight Loss                                                 | 0.86 (0.56, 1.32)        |
| Fluid and Electrolyte Disorders                             | 2.90 (1.57, 5.34)        |
| Blood Loss Anemia                                           | 2.33 (1.47, 3.69)        |
| Deficiency Anemia                                           | 0.56 (0.34, 0.92)        |
| Alcohol Abuse                                               | 0.73 (0.33, 1.63)        |
| Drug Abuse                                                  | 0.62 (0.29, 1.34)        |
| Psychoses                                                   | 1.16 (0.65, 2.09)        |
| Depression                                                  | 0.65 (0.42, 1.00)        |

¹HR = Subdistribution Hazard Ratio, CI = Confidence Interval
²Bold values indicate statistical significance
Studying the risk factors for readmission post-discharge, we found that cardiac arrhythmias (Odds Ratio (OR): 1.85; 95% CI: 1.12-3.13), peripheral vascular disorders (1.66; 1.01-2.71), weight loss (1.69; 1.10-2.59), fluid and electrolyte disorders (1.84; 1.08, 3.22), blood loss anemia (1.81; 1.06-3.08), and depression (2.20; 1.42-3.42) were significantly associated with higher odds of readmission, while older age (per ten years) was associated with a 16% lower odds of readmission (0.84; 0.74-0.95) and chronic pulmonary disease had lower odds of readmission (0.63; 0.40-0.98; Supplement C, Table S4). These results were qualitatively consistent with a sensitivity analysis which restricted index hospitalizations and subsequent readmissions to instances where COVID-19 was the reason for admission (Supplement D, Table S5).

Discussion

Leveraging EMR data from a regional medical center managing COVID-19, this study enriches the literature with a large COVID-19 positive patient cohort and a longer follow-up period to observe evolving patient outcomes. Differing outcomes associated with demographic characteristics such as age, sex, and race, which have become particularly salient,[20, 22, 37, 58-60] were corroborated in this study. Notably, after adjusting for all other risk factors, Black patients had lower healthcare utilization rates, but higher hospitalization and mortality rates. Previous work has similarly noted these differences in adverse COVID-19 outcomes between Black and non-Black patients.[61-65] Higher comorbidity burden was also shown to be associated with these outcomes, particularly among patients with chronic pulmonary disease, diabetes, and cardiac complications.[15, 48–51]

With regards to less-studied post-hospitalization outcomes, fluid and electrolyte disorders and blood loss anemia were associated with higher readmission and higher post-hospitalization mortality rates. While mechanisms of these associations are unknown, one potential explanation...
is syndrome of inappropriate antidiuretic hormone (SIADH) secretion. Hyponatremia and SIADH have a known association with severe COVID-19 infection, as reported previously.[66–68] However, patients in our study population who were broadly indicated for fluid and electrolyte disorders have imbalances that span the range of sodium and potassium, acidosis, alkalosis, and volume depletion which coincide with each other and worsened COVID-19 outcomes.[69-71] Additionally, blood loss anemia may be aggravated by repeated blood tests, particularly, in those who developed pneumonia and acute respiratory distress syndrome (ARDS), or due to gastrointestinal bleeding.[72-80] Lastly, depression was found to be associated with higher odds of readmission, but lower mortality rates. It is being shown that patients who experienced severe COVID-19 and had lasting long-term morbidity were more likely to develop depression or other psychiatric disorder,[81] and thus might be readmitted due to the residual effects of COVID-19.[82]

Patient age and pre-existing chronic pulmonary disease were associated with lower odds of readmission, but higher mortality rates, suggesting a greater risk of in-hospital mortality for these severe risk factors.[53, 83-86] Cardiac arrhythmias, peripheral vascular disorders, and coagulopathy were also associated with higher readmissions and post-hospitalization mortality. Cardiac complications among severe COVID-19 cases have been shown to include myocardial injury, heart failure, and sudden cardiac arrest.[87–90] Such involvement poses potential implications for monitoring patient prognosis during an inpatient stay, as well as long-term surveillance in recovered cases. Concerning risk factors associated with the two competing shorter-term hospitalization outcomes, discharge and in-hospital death, we identified that older age, diabetes with complications, coagulopathy, fluid and electrolyte disorders, and blood loss anemia were associated with lower rates of discharge and higher rates of in-hospital death. The
findings corroborate previous results for in-hospital mortality, which did not take into account patient discharge as a competing event. To our knowledge, we are among the first few to consider discharge versus in-hospital mortality among COVID-19 patients under a competing risk regression framework. Ignoring their competing relationship can lead to biased estimates of effects of risk factors for either event. A recent study investigated COVID-19 hospitalization outcomes in a similar manner, reporting a subdistribution hazard ratio for patient age, adjusting for sex. This result, in a smaller, localized international cohort, is consistent with our findings on age.

Lastly, we failed to detect significant associations between risk factors such as obesity and renal failure, which have been studied extensively in the COVID-19 literature. While obesity, being pro-inflammatory, is a well-established risk factor for worsened outcomes in COVID-19 patients, we failed to detect a statistically significant obesity effect in this subset of patients. Similarly, renal involvement with COVID-19 is well-studied, though multifactorial in nature. We believe this possibly due to (1) potential collinearity with more down-stream risk factors included in our models and (2) a lack of statistical power to detect these effects, as the directions of several effects were consistent with previously established associations with obesity and renal failure, though not statistically significant. As a sensitivity check, we fit univariate models for each of the comorbidity conditions, adjusted for patient demographics (age, sex, and race). These results show significant associations, marginally, for these risk factors (see Supplement E).

Limitations

First, as a small number of patients who transferred in from other institutions did not have medical history data, we had to remove them from analysis, though their impacts on our results
were limited. Second, as this study was based exclusively on patients of Michigan Medicine, there may be biases in the patient mix, affecting the generalizability to more diverse populations or other geographic areas. On the other hand, these patients did offer an opportunity to study COVID-19 outcomes in a local region that had been severely impacted by the pandemic. Third, this was a retrospective study of an existing EMR database. As such, we are limited in our ability to draw causal interpretations from these results. In addition, due to the nature of EMR data, there is always the possibility for misclassification bias and/or inaccurate data entry. Lastly, future work, with longer follow-up, should focus on the residual impact of COVID-19 among recovered patients to elucidate the effect of lasting symptoms and acquired comorbidity burden on long-term quality of life and mortality.

**Conclusions**

Several lessons can be learned with our analysis. First, there exist socio-demographic inequalities in healthcare access and COVID-19 outcomes among COVID-19 patients; after adjusting for all comorbid and other demographic conditions, being Black was associated higher hospitalization and mortality rates. Second, chronic pulmonary disease, diabetes, and cardiac complications were among the most significant risk factors for these outcomes, suggesting more targeted screening among at-risk patients. Third, among hospitalized COVID-19 patients, poorer outcomes may be disproportionately associated with additional risk factors, namely cardiac complications such as arrhythmias and coagulopathy, as well as other comorbid conditions such as peripheral vascular disorders, fluid and electrolyte disorders, blood loss anemia, and abnormal weight loss. Therefore, increased testing and vaccination efforts in these particularly susceptible populations are necessary to prevent residual disease burden. Lastly, these analysis results may inform providers in emergency departments or critical care settings of treatment priorities,
empower healthcare stakeholders with effective disease management strategies, and aid health policy makers in optimizing allocations of medical resources.
Acknowledgements

We thank Dr. Brahmajee Nallamothu for leading the development and curation of DataDirect, a newly launched, GPU-based analytics platform through the Michigan Medicine Precision Health Initiative. We are also grateful to Anisa Driscoll and Kate Smith for their continued analytical support with respect to database management, data processing, and use of the DataDirect platform.
References

1. Office of the Governor of Michigan. Executive Order 2020–04(COVID-19) - Declaration of State of Emergency. 2020. Accessed: 2021-03-10

2. Oster AM, Kang GJ, Cha AE, et al. Trends in number and distribution of COVID-19 hotspot counties—United States, March 8–July 15, 2020. Morbidity and Mortality Weekly Report. 2020;69(33):1127.

3. Woolf SH, Chapman DA, Lee JH. COVID-19 as the leading cause of death in the United States. JAMA. 2021;325(2):123–124.

4. Coronavirus - Michigan Data. Michigan.gov Coronavirus Data.

5. Yang T, Shen K, He S, et al. CovidNet: To Bring Data Transparency in the Era of COVID-19. 2020.

6. Mogaji E. Financial vulnerability during a pandemic: insights for coronavirus disease (COVID-19). Mogaji, E. 2020:57–63.

7. Martin A, Markhvida M, Hallegatte S, Walsh B. Socio-economic impacts of COVID-19 on household consumption and poverty. Economics of Disasters and Climate Change. 2020;4(3):453–479.

8. Madhavan S, Bastarache L, Brown JS, et al. Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centers. Journal of the American Medical Informatics Association. 2021;28(2):393–401.

9. Santeusanio AD, Zendel A, Fenig Y, et al. Kidney transplantation using lymphocyte depleting induction and standard maintenance immunosuppression at the height of the SARS-CoV-2 pandemic in New York City: A single-center experience. Clinical Transplantation. 2020;34(9):e14055.

10. Montenovo L, Jiang X, Rojas FL, et al. Determinants of disparities in COVID-19 job losses. tech. rep.National Bureau of Economic Research 2020.
11. Karpman M, Zuckerman S, Gonzalez D, Kenney GM. The COVID-19 pandemic is straining families’ abilities to afford basic needs. *Washington, DC: Urban Institute*. 2020;500.

12. Chen CYC, Byrne E, Vélez T. Impact of the 2020 pandemic of COVID-19 on Families with School-aged Children in the United States: Roles of Income Level and Race. *Journal of Family Issues*. 2021:0192513X21994153.

13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–1242.

14. Rod J, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. *Revista de Saude Publica*. 2020;54:60.

15. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*. 2020;10.

16. Jordan RE, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. 2020.

17. Mikami T, Miyashita H, Yamada T, et al. Risk factors for mortality in patients with COVID-19 in New York City. *Journal of General Internal Medicine*. 2021;36(1):17–26.

18. Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)- associated hospitalization surveillance network (COVID-NET). *Clinical Infectious Diseases*. 2020.

19. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. *JAMA Network Open*. 2020;3(12):e2029058–e2029058.

20. Gu T, Mack JA, Salvatore M, et al. Characteristics associated with Racial/Ethnic disparities in COVID-19 outcomes in an academic health care system. *JAMA Network Open*. 2020;3(10):e2025197–e2025197.

21. Rogers TN, Rogers CR, VanSant-Webb E, Gu LY, Yan B, Qeadan F. Racial Disparities
in COVID-19 Mortality Among Essential Workers in the United States. *World Medical & Health Policy*. 2020;12(3):311–327.

22. Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in obesity and by ethnicity/race. 2020.

23. Alcendor DJ. Racial disparities-associated COVID-19 mortality among minority populations in the US. *Journal of Clinical Medicine*. 2020;9(8):2442.

24. Karmakar M, Lantz PM, Tipirneni R. Association of social and demographic factors with COVID-19 incidence and death rates in the US. *JAMA Network Open*. 2021;4(1):e2036462–e2036462.

25. Drefahl S, Wallace M, Mussino E, et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. *Nature Communications*. 2020;11(1):1–7.

26. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, Parra-Rodríguez L. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. *PLoS One*. 2020;15(9):e0238905.

27. Kontis V, Bennett JE, Rashid T, et al. Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. *Nature Medicine*. 2020:1–10.

28. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. *PLoS Medicine*. 2020;17(9):e1003379.

29. Salerno S, Zhao Z, Prabhu Sankar S, et al. Patterns of repeated diagnostic testing for COVID-19 in relation to patient characteristics and outcomes. *Journal of Internal Medicine*. 2021;289(5):726–737.

30. Bilal U, Barber S, Diez-Roux AV. Early evidence of disparities in COVID-19 Testing in US Cities. *medRxiv*. 2020.
31. West C, Montori V, Sampathkumar P. COVID-19 Testing: The Threat of False-Negative Results. *Mayo Clinic Proceedings*. 2020;95(6):1127–1129.

32. Venkatesan P. The changing demographics of COVID-19. *The Lancet Respiratory Medicine*. 2020;8(12):e95.

33. Jin J, Agarwala N, Kundu P, et al. Individual and community-level risk for COVID-19 mortality in the United States. *Nature Medicine*. 2021;27(2):264–269.

34. Unwin HJT, Mishra S, Bradley VC, et al. State-level tracking of COVID-19 in the United States. *Nature Communications*. 2020;11(1):1–9.

35. Daugherty AM, Arble EP. Prevalence of mental health symptoms in residential healthcare workers in Michigan during the covid-19 pandemic. *Psychiatry Research*. 2020.

36. Spector-Bagdady K, Higgins PD, Aaronson KD, et al. Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan Medicine. *Clinical Infectious Diseases*. 2020;71(16):2187–2190.

37. Salvatore M, Gu T, Mack JA, et al. A phenome-wide association study (PheWAS) of COVID-19 outcomes by race using the electronic health records data in Michigan Medicine. *Journal of Clinical Medicine*. 2021;10(7):1351.

38. DataDirect. Precision Health Analytics Platform. 2021.

39. Moser DK, Yamokoski L, Sun JL, et al. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. *Journal of Cardiac Failure*. 2009;15(9):763–769.

40. Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. *International Journal of Cardiology*. 2013;163(3):320–325.

41. Crabb BT, Lyons A, Bale M, et al. Comparison of International Classification of Diseases and Related Health Problems, Tenth Revision Codes With Electronic Medical Records
Among Patients With Symptoms of Coronavirus Disease 2019. *JAMA Network Open*. 2020;3(8):e2017703–e2017703.

42. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Medical Care*. 1998;8–27.

43. Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. *Medical Care*. 2009:626–633.

44. Quan H, Sundararajan V, Halfon P, *et al.* Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical Care*. 2005:1130–1139.

45. Thompson NR, Fan Y, Dalton JE, *et al.* A new Elixhauser-based comorbidity summary measure to predict in-hospital mortality. *Medical Care*. 2015;53(4):374.

46. Ladha KS, Zhao K, Quraishi SA, *et al.* The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients. *BMJ Open*. 2015;5(9).

47. Simard M, Sirois C, Candas B. Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD-9 and ICD-10. *Medical Care*. 2018;56(5):441–447.

48. Centers for Disease Control and Prevention. Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. 2020.

49. Ebinger JE, Achamallah N, Ji H, *et al.* Pre-existing traits associated with Covid-19 illness severity. *PloS One*. 2020;15(7):e0236240.

50. Williamson EJ, Walker AJ, Bhaskaran K, *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430–436.

51. Alqahtani JS, Oyelade T, Aldhahir AM, *et al.* Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. *PloS One*. 2020;15(5):e0233147.
52. Khan MMA, Khan MN, Mustagir MG, Rana J, Islam MS, Kabir MI. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. Journal of Global Health. 2020;10(2).

53. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215.

54. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049.

55. Coxe S, West SG, Aiken LS. The analysis of count data: A gentle introduction to Poisson regression and its alternatives. Journal of Personality Assessment. 2009;91(2):121–136.

56. Therneau TM, Grambsch PM. The cox model. in Modeling Survival Data: Extending the Cox Model:39– 77Springer 2000.

57. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94(446):496–509.

58. Patel AP, Paranjpe MD, Kathiresan NP, Rivas MA, Khera AV. Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. International Journal for Equity in Health. 2020;19(1):1–4.

59. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. New England Journal of Medicine. 2020;382(26):2534–2543.

60. Gausman J, Langer A. Sex and gender disparities in the COVID-19 pandemic. Journal of Women’s Health. 2020;29(4):465–466.

61. Lieberman-Cribbin W, Tuminello S, Flores RM, Taioli E. Disparities in COVID-19 testing and positivity in New York City. American Journal of Preventive Medicine. 2020;59(3):326–332.

62. Khatana SAM, Groeneveld PW. Health disparities and the coronavirus disease 2019
COVID-19 pandemic in the USA. *Journal of General Internal Medicine.* 2020;35:2431–2432.

63. Chunara R, Zhao Y, Chen J, et al. Telemedicine and healthcare disparities: a cohort study in a large healthcare system in New York City during COVID-19. *Journal of the American Medical Informatics Association.* 2021;28(1):33–41.

64. Wiley Z, Kubes JN, Cobb J, et al. Age, comorbid conditions, and racial disparities in COVID-19 outcomes. *Journal of Racial and Ethnic Health Disparities.* 2021:1–7.

65. Ravi K. Ethnic disparities in COVID-19 mortality: are comorbidities to blame?. in *The COVID-19 Reader.* Routledge 2020.

66. Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MF. COVID-19-associated SIADH: a clue in the times of pandemic!. *American Journal of Physiology-Endocrinology and Metabolism.* 2020;318(6):E882–E885.

67. Habib MB, Sardar S, Sajid J. Acute symptomatic hyponatremia in setting of SIADH as an isolated presentation of COVID-19. *IDCases.* 2020;21:e00859.

68. Khalangot M. COVID-19 and SIADH relations: impact of the positive pressure ventilation. *American Journal of Physiology-Endocrinology and Metabolism.* 2020;319(1):E196–E196.

69. Alfano, G., Ferrari, A., Fontana, F., Perrone, R., Mori, G., Ascione, E., et al. (2021). Hypokalemia in Patients with COVID-19. *Clinical and experimental nephrology,* 25(4), 401-409.

70. Moreno-P, O., Leon-Ramirez, J. M., Fuertes-Kenneally, L., Perdiguer, M., Andres, M., Garcia-Navarro, M., et al. (2020). Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. *International Journal of Infectious Diseases,* 100, 449-454.

71. De Carvalho, H., Richard, M. C., Chouiheh, T., Goffinet, N., Le Bastard, Q., Freund, Y., et al. (2021). Electrolyte imbalance in COVID-19 patients admitted to the Emergency Department: a case–control study. *Internal and Emergency Medicine,* 1-6.
72. Fan BE, Ong KH, Chan SSW, et al. Blood and blood product use during COVID-19 infection. *American Journal of Hematology.* 2020.

73. Baron D, Franchini M, Goobie S, et al. Patient blood management during the COVID–19 pandemic: a narrative review. *Anaesthesia.* 2020;75(8):1105–1113.

74. Cavaliere, K., Levine, C., Wander, P., Sejpal, D. V., et al. (2020). Management of upper GI bleeding in patients with COVID-19 pneumonia. *Gastrointestinal endoscopy,* 92(2), 454.

75. Trindade, A. J., Izard, S., Coppa, K., Hirsch, J. S., Lee, C., Satapathy, S. K., & Northwell COVID-19 Research Consortium. (2021). Gastrointestinal bleeding in hospitalized COVID-19 patients: a propensity score matched cohort study. *Journal of Internal Medicine,* 289(6), 887-894.

76. Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K, Yatzkan G. Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review. *Tropical Medicine and Infectious Disease.* 2020;5(3):112.

77. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet.* 2020;395(10223):497–506.

78. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Internal Medicine.* 2020;180(7):934–943.

79. Baron DM, Lei C, Berra L. Old, older, the oldest: red blood cell storage and the potential harm of using older red blood cell concentrates. *Current Opinion in Anesthesiology.* 2020;33(2):234–239.

80. Vlaar AP, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. *Transfusion.* 2019;59(7):2465–2476.

81. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet.* 2021.

82. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19
and psychiatric disorder: retrospective cohort studies of 62,354 COVID-19 cases in the USA. 

The Lancet Psychiatry. 2021;8(2):130–140.

83. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. New England Journal of Medicine. 2020;382(25):e102.

84. Wu F, Zhou Y, Wang Z, et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study. Journal of Thoracic Disease. 2020;12(5):1811.

85. Pranata R, Soeroto A, Huang I, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. The International Journal of Tuberculosis and Lung Disease. 2020;24(8):838–843.

86. Estiri H, Strasser ZH, Klann JG, Naseri P, Waghokar KB, Murphy SN. Predicting COVID-19 mortality with electronic medical records. NPJ Digital Medicine. 2021;4(1):1–10.

87. Ma KL, Liu ZH, Cao CF, et al. COVID-19 myocarditis and severity factors: an adult cohort study. medRxiv. 2020.

88. Beşler MS, Arslan H. Acute myocarditis associated with COVID-19 infection. The American Journal of Emergency Medicine. 2020;38(11):2489–e1.

89. Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984–1990.

90. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020;17(9):1439–1444.

91. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.

92. Rastad H, Karim H, Ejtahed HS, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabetology & Metabolic Syndrome. 2020;12(1):1–11.
93. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *Journal of Thrombosis and Haemostasis*. 2020;18(6):1324–1329.

94. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiology*. 2020;5(7):802–810.

95. Shi M, Chen L, Yang Y, et al. Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: A multicenter descriptive study. *Journal of Clinical Laboratory Analysis*. 2020;34(9):e23415.

96. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. *Journal of the American College of Cardiology*. 2020;76(16):1815–1826.

97. Oulhaj A, Ahmed LA, Prattes J, et al. The competing risk between in-hospital mortality and recovery: A pitfall in COVID-19 survival analysis research. *medRxiv*. 2020.

98. Goel A, Raizada A, Agrawal A, et al. Correlates of in-hospital COVID-19 deaths: a competing risks survival time analysis of retrospective mortality data. *Disaster Medicine and Public Health Preparedness*. 2021:1–27.

99. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. *Obesity*. 2020;28(6):1005–1005.3.

100. Hussain A, Mahawar K, Xia Z, Yang W, Shamsi EH. Obesity and mortality of COVID-19. Meta-analysis. *Obesity Research & Clinical Practice*. 2020.4.

101. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. *Obesity*. 2020;28(9):1595–1599.5.

102. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Annals of Internal Medicine*. 2020;173(10):773–78
103. Raza, A., Estepa, A., Chan, V., & Jafar, M. S. (2020). Acute renal failure in critically ill COVID-19 patients with a focus on the role of renal replacement therapy: a review of what we know so far. *Cureus*, 12(6).

104. Khoshdel-Rad, N., Zahmatkesh, E., Shpichka, A., Timashev, P., & Vosough, M. (2021). Outbreak of chronic renal failure: will this be a delayed heritage of COVID-19?.

105. Zaim, S., Chong, J. H., Sankaranarayanan, V., & Harky, A. (2020). COVID-19 and multiorgan response. *Current problems in cardiology*, 45(8), 100618.

106. Adapa, S., Aeddula, N. R., Konala, V. M., Chenna, A., Naramala, S., Madhira, B. R., et al. (2020). COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. *Journal of clinical medicine research*, 12(5), 276.
Supporting Information Captions

A. Comorbidity Conditions and Additional Comparisons Between Race

B. Fine-Gray Model for Competing Risks

C. Sensitivity Analysis
All Patients ($n = 6,731$)

Outcome 1a: Rate of Medical Encounters

Outcome 1b: Hospitalization-Free Survival

Never Hospitalized ($n = 5,784$)

Hospitalized ($n = 947$)

Outcome 2a-b: Discharge vs. In-Hospital Death

Discharged ($n = 840$)

Outcome 2c: Readmission

Never Readmitted ($n = 680$)

Readmitted ($n = 160$)

Outcome 1c: Overall Survival

Alive ($n = 5,765$)

Died ($n = 19$)

Alive ($n = 663$)

Died ($n = 17$)

Alive ($n = 150$)

Died ($n = 10$)

Died ($n = 107$)
